EMBARK, gene therapy for the treatment of DMD
Sarepta Therapeutics announces initiation of EMBARK, a global p0ivotal study of SRP-9001, gene therapy for the treatment of DMD (Duchenne Muscular Dystrophy) Original press release > CAMBRIDGE, Mass., Oct. 04, […]
Part B of MOMENTUM study of SRP-5051 in patients with DMD
Sarepta Therapeutics to initiate Part B of MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy (DMD) amenable to Exon 51 skipping following positive interactions with FDA Original press […]
World Duchenne Awareness Day 2021
September 7 is World Duchenne Awareness Day. On this day, we raise awareness for Duchenne and Becker muscular dystrophy (DMD and BMD) around the globe. An initiative coordinated by the […]
ENDEAVOR, gene therapy for DMD
Sarepta Therapeutics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy, SRP-9001, demonstrates robust expression and consistent safety profile using Sarepta’s commercial process material. The first 11 participants […]
Positive clinical results from phase 2 MOMENTUM study
Sarepta Therapeutics reports positive clinical results from phase 2 MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51 Results suggest a highly potent next-generation […]
Genethon announces First Patient dosed in Clinical Trial
Genethon announces First Patient dosed in Clinical Trial of Investigational Gene therapy GNT004 for Duchenne Muscular Dystrophy. Communiqué de presse original > Genethon A first participant was dosed at I-Motion, […]
